Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 20;15:1413233. doi: 10.3389/fimmu.2024.1413233

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2024 López, Depreux, Bielsa, Roger, Quirant-Sanchez, Basagaña, Jurgens, Padró, Miquel, Martinez-Caceres and Teniente-Serra

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Changes in the percentage of CD4 and CD8 T cells expressing CD38 and HLA-DR in peripheral blood of CSU treated with NID, treated with omalizumab and HD. Percentages of (A) HLA-DR^-CD38⁺ CD4 T cells, (B) HLA-DR⁺CD38^- CD4 T cells, (C) HLA-DR⁺CD38⁺ CD4 T cells, (D) HLA-DR^-CD38⁺ CD8 T cells, (E) FILA-DR⁺CD38^- CD8 T cells, (F) HLA-DR⁺CD38⁺ CD8 T cells in peripheral blood of HD, NID and CSU patients under omalizumab treatment. CSU, chronic spontaneous urticaria; HD, healthy donors (n = 50); NID, non-immunomodulatory drugs (n = 27); OZB, omalizumab (n = 24).